Guillemette Antoni1, Cécile Tremblay2, Constance Delaugerre3, Isabelle Charreau1, Eric Cua4, Daniela Rojas Castro5, François Raffi6, Julie Chas7, Thomas Huleux8, Bruno Spire9, Catherine Capitant1, Laurent Cotte10, Laurence Meyer11, Jean-Michel Molina3. 1. Institut national de la santé et de la recherche médicale (INSERM) SC10 US19, Villejuif, France. 2. Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. 3. Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France; INSERM UMR 944, Biologie Cellulaire des Infections Virales, Paris, France; Université de Paris, Paris, France. 4. Hôpital de l'Archet, Nice, France. 5. Coalition PLUS, Pantin, France; Aix Marseille University, INSERM, Institut de Recherche pour le Développement, Sciences Economiques & Sociales de la Santé et Traitement de l'Information Médicale, Marseille, France; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France. 6. INSERM CIC 1413, Nantes, France; Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nantes, Nantes, France. 7. Hôpital Tenon, Paris, France. 8. Hôpital Gustave Dron, Centre Hospitalier Universitaire de Tourcoing, France. 9. Aix Marseille University, INSERM, Institut de Recherche pour le Développement, Sciences Economiques & Sociales de la Santé et Traitement de l'Information Médicale, Marseille, France; Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France. 10. Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France. 11. Institut national de la santé et de la recherche médicale (INSERM) SC10 US19, Villejuif, France; Université Paris Sud, Université Paris Saclay, Paris, France. Electronic address: laurence.meyer@inserm.fr.
Abstract
BACKGROUND: ANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative reduction of HIV-1 incidence compared with placebo among men who have sex with men at high risk of HIV. We aimed to investigate whether on-demand PrEP was similarly effective among individuals with lower exposure to HIV risk. METHODS: Participants in the ANRS IPERGAY trial were randomly assigned to receive PrEP (fixed-dose combination of 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill) or placebo. The primary endpoint was the diagnosis of HIV-1 infection. Pill uptake was assessed by counting returned pills at each follow-up and by estimating tenofovir concentration from frozen plasma samples. Participants were interviewed at each visit to assess the pattern of PrEP use. All participants enrolled in the modified intention-to-treat population of the double-blind phase of the ANRS IPERGAY trial were eligible for this post-hoc analysis. We calculated the total follow-up time for periods of less frequent sexual intercourse with high PrEP adherence (15 pills or fewer per month taken systematically or often during sexual intercourse). To estimate the time of HIV acquisition, fourth-generation HIV-1/2ELISA assays, plasma HIV-1 RNA assays, and western blot analyses were done with use of frozen samples, and the stage of HIV infection was defined according to Fiebig staging. HIV incidence was compared between the two treatment groups among individuals who had less frequent sexual intercourse with high PrEP adherence. The ANRS IPERGAY trial is registered with ClinicalTrials.gov, NCT01473472. FINDINGS:400 participants who were randomly assigned to receive PrEP (n=199) or placebo (n=201) between Feb 22, 2012, and Oct 17, 2014, were included in this analysis. 270 participants had at least one period of less frequent sexual intercourse with high PrEP adherence during the study, representing 134 person-years of follow-up and 31% of the total study follow-up. During these periods, participants in both groups reported a median of 5·0 (IQR 2·0-10·0) episodes of sexual intercourse per month and used a median of 9·5 (6·0-13·0) pills per month. Six HIV-1 infections were diagnosed in the placebo group (HIV incidence of 9·2 per 100 person-years; 95% CI 3·4-20·1) and none were diagnosed in the tenofovir disoproxil fumarate plus emtricitabine arm (HIV incidence of 0 per 100 person-years; 0-5·4; p=0·013), with a relative reduction of HIV incidence of 100% (95% CI 39-100). INTERPRETATION: A choice between daily or on-demand PrEP regimens could be offered to men who have sex with men who have less frequent sexual intercourse. FUNDING: ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), the Canadian HIV Trials Network, Fonds Pierre Bergé (Sidaction), Gilead Sciences, and the Bill & Melinda Gates Foundation.
RCT Entities:
BACKGROUND: ANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative reduction of HIV-1 incidence compared with placebo among men who have sex with men at high risk of HIV. We aimed to investigate whether on-demand PrEP was similarly effective among individuals with lower exposure to HIV risk. METHODS:Participants in the ANRS IPERGAY trial were randomly assigned to receive PrEP (fixed-dose combination of 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill) or placebo. The primary endpoint was the diagnosis of HIV-1 infection. Pill uptake was assessed by counting returned pills at each follow-up and by estimating tenofovir concentration from frozen plasma samples. Participants were interviewed at each visit to assess the pattern of PrEP use. All participants enrolled in the modified intention-to-treat population of the double-blind phase of the ANRS IPERGAY trial were eligible for this post-hoc analysis. We calculated the total follow-up time for periods of less frequent sexual intercourse with high PrEP adherence (15 pills or fewer per month taken systematically or often during sexual intercourse). To estimate the time of HIV acquisition, fourth-generation HIV-1/2 ELISA assays, plasma HIV-1 RNA assays, and western blot analyses were done with use of frozen samples, and the stage of HIV infection was defined according to Fiebig staging. HIV incidence was compared between the two treatment groups among individuals who had less frequent sexual intercourse with high PrEP adherence. The ANRS IPERGAY trial is registered with ClinicalTrials.gov, NCT01473472. FINDINGS: 400 participants who were randomly assigned to receive PrEP (n=199) or placebo (n=201) between Feb 22, 2012, and Oct 17, 2014, were included in this analysis. 270 participants had at least one period of less frequent sexual intercourse with high PrEP adherence during the study, representing 134 person-years of follow-up and 31% of the total study follow-up. During these periods, participants in both groups reported a median of 5·0 (IQR 2·0-10·0) episodes of sexual intercourse per month and used a median of 9·5 (6·0-13·0) pills per month. Six HIV-1 infections were diagnosed in the placebo group (HIV incidence of 9·2 per 100 person-years; 95% CI 3·4-20·1) and none were diagnosed in the tenofovir disoproxil fumarate plus emtricitabine arm (HIV incidence of 0 per 100 person-years; 0-5·4; p=0·013), with a relative reduction of HIV incidence of 100% (95% CI 39-100). INTERPRETATION: A choice between daily or on-demand PrEP regimens could be offered to men who have sex with men who have less frequent sexual intercourse. FUNDING: ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), the Canadian HIV Trials Network, Fonds Pierre Bergé (Sidaction), Gilead Sciences, and the Bill & Melinda Gates Foundation.
Authors: Dana Ogaz; Louise Logan; Tyrone J Curtis; Lorraine McDonagh; Luis Guerra; Daniel Bradshaw; Poorvi Patel; Chiara Macri; Gary Murphy; O Noel Gill; Anne M Johnson; Anthony Nardone; Fiona Burns Journal: BMC Public Health Date: 2022-06-03 Impact factor: 4.135
Authors: Jing Zhang; Chunyan Li; Junjie Xu; Zhili Hu; Sarah E Rutstein; Joseph D Tucker; Jason J Ong; Yongjun Jiang; Wenqing Geng; Sarah T Wright; Myron S Cohen; Hong Shang; Weiming Tang Journal: Lancet HIV Date: 2022-04 Impact factor: 16.070
Authors: Whitney C Sewell; Victoria E Powell; Kenneth H Mayer; Aileen Ochoa; Douglas S Krakower; Julia L Marcus Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771
Authors: Maria Pyra; Laura Rusie; Michael Castro; Kristin Keglovitz Baker; Moira McNulty; Nick Bohm; Andrei Prokurat; John Schneider Journal: AIDS Date: 2020-11-01 Impact factor: 4.632
Authors: Peter R Chai; Georgia Goodman; Majo Bustamante; Lizette Mendez; Yassir Mohamed; Kenneth H Mayer; Edward W Boyer; Rochelle K Rosen; Conall O'Cleirigh Journal: AIDS Behav Date: 2020-11-21